Cargando…

CD4(+) T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients

AIM: To characterize peripheral blood natural killer (NK) cells phenotypes by flow cytometry as potential biomarker of liver fibrosis in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients. METHODS: Peripheral mononuclear cells from 24 HIV/HCV (HBV negative) coinfected and...

Descripción completa

Detalles Bibliográficos
Autores principales: Laufer, Natalia, Ojeda, Diego, Polo, María Laura, Martinez, Ana, Pérez, Héctor, Turk, Gabriela, Cahn, Pedro, Zwirner, Norberto Walter, Quarleri, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596314/
https://www.ncbi.nlm.nih.gov/pubmed/28951779
http://dx.doi.org/10.4254/wjh.v9.i25.1073
_version_ 1783263508460208128
author Laufer, Natalia
Ojeda, Diego
Polo, María Laura
Martinez, Ana
Pérez, Héctor
Turk, Gabriela
Cahn, Pedro
Zwirner, Norberto Walter
Quarleri, Jorge
author_facet Laufer, Natalia
Ojeda, Diego
Polo, María Laura
Martinez, Ana
Pérez, Héctor
Turk, Gabriela
Cahn, Pedro
Zwirner, Norberto Walter
Quarleri, Jorge
author_sort Laufer, Natalia
collection PubMed
description AIM: To characterize peripheral blood natural killer (NK) cells phenotypes by flow cytometry as potential biomarker of liver fibrosis in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients. METHODS: Peripheral mononuclear cells from 24 HIV/HCV (HBV negative) coinfected and 5 HIV/HCV/HBV seronegative individuals were evaluated. HIV/HCV coinfected patients were divided in to groups: G1, patients with METAVIR F0-F2 and G2, patients with METAVIR F3-F4. NK surface cell staining was performed with: Anti-CD3(APC/Cy7), anti-CD56(PE/Cy5), anti-CD57(APC), anti-CD25(PE), anti-CD69(FITC), anti-NKp30(PE), anti-NKp46(PE/Cy7), anti-NKG2D(APC), anti-DNAM(FITC); anti-CD62L (PE/Cy7), anti-CCR7(PE), anti-TRAIL(PE), anti-FasL(PE), anti CD94(FITC). Flow cytometry data acquisition was performed on BD FACSCanto, analyzed using FlowJo software. Frequency of fluorescence was analyzed for all single markers. Clinical records were reviewed, and epidemiological and clinical data were obtained. RESULTS: Samples from 11 patients were included in G1 and from 13 in G2. All patients were on ARV, with undetectable HIV viral load. Liver fibrosis was evaluated by transient elastography in 90% of the patients and with biopsy in 10% of the patients. Mean HCV viral load was (6.18 ± 0.7 log(10)). Even though, no major significant differences were observed between G1 and G2 regarding NK surface markers, it was found that patients with higher liver fibrosis presented statistically lower percentage of NK cells than individual with low to mild fibrosis and healthy controls (G2: 5.4% ± 2.3%, G1: 12.6% ± 8.2%, P = 0.002 and healthy controls 12.2% ± 2.7%, P = 0.008). It was also found that individuals with higher liver fibrosis presented lower CD4 LT count than those from G1 (G2: 521 ± 312 cells/μL, G1: 770 ± 205 cells/μL; P = 0.035). CONCLUSION: Higher levels of liver fibrosis were associated with lower percentage of NK cells and LTCD4(+) count; and they may serve as noninvasive biomarkers of liver damage.
format Online
Article
Text
id pubmed-5596314
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-55963142017-09-26 CD4(+) T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients Laufer, Natalia Ojeda, Diego Polo, María Laura Martinez, Ana Pérez, Héctor Turk, Gabriela Cahn, Pedro Zwirner, Norberto Walter Quarleri, Jorge World J Hepatol Observational Study AIM: To characterize peripheral blood natural killer (NK) cells phenotypes by flow cytometry as potential biomarker of liver fibrosis in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients. METHODS: Peripheral mononuclear cells from 24 HIV/HCV (HBV negative) coinfected and 5 HIV/HCV/HBV seronegative individuals were evaluated. HIV/HCV coinfected patients were divided in to groups: G1, patients with METAVIR F0-F2 and G2, patients with METAVIR F3-F4. NK surface cell staining was performed with: Anti-CD3(APC/Cy7), anti-CD56(PE/Cy5), anti-CD57(APC), anti-CD25(PE), anti-CD69(FITC), anti-NKp30(PE), anti-NKp46(PE/Cy7), anti-NKG2D(APC), anti-DNAM(FITC); anti-CD62L (PE/Cy7), anti-CCR7(PE), anti-TRAIL(PE), anti-FasL(PE), anti CD94(FITC). Flow cytometry data acquisition was performed on BD FACSCanto, analyzed using FlowJo software. Frequency of fluorescence was analyzed for all single markers. Clinical records were reviewed, and epidemiological and clinical data were obtained. RESULTS: Samples from 11 patients were included in G1 and from 13 in G2. All patients were on ARV, with undetectable HIV viral load. Liver fibrosis was evaluated by transient elastography in 90% of the patients and with biopsy in 10% of the patients. Mean HCV viral load was (6.18 ± 0.7 log(10)). Even though, no major significant differences were observed between G1 and G2 regarding NK surface markers, it was found that patients with higher liver fibrosis presented statistically lower percentage of NK cells than individual with low to mild fibrosis and healthy controls (G2: 5.4% ± 2.3%, G1: 12.6% ± 8.2%, P = 0.002 and healthy controls 12.2% ± 2.7%, P = 0.008). It was also found that individuals with higher liver fibrosis presented lower CD4 LT count than those from G1 (G2: 521 ± 312 cells/μL, G1: 770 ± 205 cells/μL; P = 0.035). CONCLUSION: Higher levels of liver fibrosis were associated with lower percentage of NK cells and LTCD4(+) count; and they may serve as noninvasive biomarkers of liver damage. Baishideng Publishing Group Inc 2017-09-08 2017-09-08 /pmc/articles/PMC5596314/ /pubmed/28951779 http://dx.doi.org/10.4254/wjh.v9.i25.1073 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Observational Study
Laufer, Natalia
Ojeda, Diego
Polo, María Laura
Martinez, Ana
Pérez, Héctor
Turk, Gabriela
Cahn, Pedro
Zwirner, Norberto Walter
Quarleri, Jorge
CD4(+) T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients
title CD4(+) T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients
title_full CD4(+) T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients
title_fullStr CD4(+) T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients
title_full_unstemmed CD4(+) T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients
title_short CD4(+) T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients
title_sort cd4(+) t cells and natural killer cells: biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis c virus-coinfected patients
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596314/
https://www.ncbi.nlm.nih.gov/pubmed/28951779
http://dx.doi.org/10.4254/wjh.v9.i25.1073
work_keys_str_mv AT laufernatalia cd4tcellsandnaturalkillercellsbiomarkersforhepaticfibrosisinhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients
AT ojedadiego cd4tcellsandnaturalkillercellsbiomarkersforhepaticfibrosisinhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients
AT polomarialaura cd4tcellsandnaturalkillercellsbiomarkersforhepaticfibrosisinhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients
AT martinezana cd4tcellsandnaturalkillercellsbiomarkersforhepaticfibrosisinhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients
AT perezhector cd4tcellsandnaturalkillercellsbiomarkersforhepaticfibrosisinhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients
AT turkgabriela cd4tcellsandnaturalkillercellsbiomarkersforhepaticfibrosisinhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients
AT cahnpedro cd4tcellsandnaturalkillercellsbiomarkersforhepaticfibrosisinhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients
AT zwirnernorbertowalter cd4tcellsandnaturalkillercellsbiomarkersforhepaticfibrosisinhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients
AT quarlerijorge cd4tcellsandnaturalkillercellsbiomarkersforhepaticfibrosisinhumanimmunodeficiencyvirushepatitiscviruscoinfectedpatients